Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy

High Blood Pressure and Cardiovascular Prevention

Volumn 13, Issue 2, 2006, Pages 47-52

  Derosa, Giuseppe ^a   Cicero, Arrigo F G ^b   D'Angelo, Angela ^a   Tinelli, Carmine ^c   Ciccarelli, Leonardina ^a   Piccinni, Mario N ^a   Pricolo, Fabio ^a   Salvadeo, Sibilla ^a   Montagna, Lorenza ^a   Fogari, Elena ^a   Gravina, Alessia ^a   Ferrari, Ilaria ^a   Galli, Simona ^a   Paniga, Sonia ^a   Fogari, Roberto ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DOXAZOSIN; GELATINASE A; GELATINASE B; LIPOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG EFFECT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LIPID ANALYSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 33745890307     PISSN: 11209879     EISSN: 11209879     Source Type: Journal    
DOI: 10.2165/00151642-200613020-00002     Document Type: Article

References (29)

1. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-7
2. Galis ZS, Sukluva GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503
3. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36: 312-8
4. Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17: 119-24
5. + channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 2004; 17: 273-6
6. Ergul A, Portik-Dobos V, Hutchinson J, et al. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 2004; 17: 775-82
7. Laviades C, Varo N, Fernandez J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-40
8. Tayebjee MH, Nadar S, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment. Am J Hypertens 2004; 17: 764-9
9. Tayebjee MH, Nadar S, MacFadyen RJ, et al. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Am J Hypertens 2004; 17: 770-4
10. Li-Saw-Hee FL, Edmunds E, Blann AD, et al. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension: relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75: 43-7
11. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-83
12. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9
13. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diab Med 1999; 16: 716-30
14. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-6
15. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978; 15: 121-30
16. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU, editor. Methods of enzymatic analysis. 2nd English ed. New York: Academic Press, Inc., 1974: 18-31
17. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-53
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
19. Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-38
20. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1959; 17: 237-46
21. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescence detection. J Chromatography 1987; 422: 43-52
22. Fujimoto N, Mouri N, Iwata K, et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 1993; 221 (1-2): 91-103
23. Fujimoto N, Hosokawa N, Iwata K, et al. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 1994; 231 (1): 79-88
24. Clark IM, Powell LK, Wright JK, et al. Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP. Matrix 1991; 11 (2): 76-85
25. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136-41
26. Tayebjee MH, MacFadyen RJ, Lip GY. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens 2003; 21: 2211-8
27. Derosa G, Cicero AF, Gaddi A, et al. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol 2005; 45 (6): 599-604
28. Courtney CH, McCance DR, Atkinson AB, et al. Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism 2003; 52 (9): 1147-52
29. Escobar E. Hypertension and coronary heart disease. J Hum Hypertens 2002; 16 Suppl. 1: S61-3